Beckley Psytech raises $80m for psychedelic meds development
pharmaphorum
AUGUST 16, 2021
The Oxford-based company had originally hoped to raise $50 million from the series B, and the scale of the financing is further evidence that repurposing psychedelic compounds as potential therapies for neuro-psychiatric disorders is a hot topic in biopharma.
Let's personalize your content